Suboxone, a drug used to treat opioid addiction, has seen significant growth in demand in the US owing to rising cases of opioid use disorder. Suboxone contains buprenorphine and naloxone, which helps to reduce withdrawal symptoms and cravings in patients undergoing treatment for opioid addiction.

The growing opioid epidemic has made America Suboxone a vital tool in combating drug abuse. Suboxone offers an alternative to methadone with less dependency and helps stabilize patients through outpatient treatment.

The United States of America Suboxone market is estimated to be valued at US$ 2,285.5 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the US Suboxone market are Indivior PLC., Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., Mallinckrodt, Lannett Co Inc., Sun Pharmaceutical Industries Ltd., and Alkem Labs.

The growing prevalence of opioid use disorder in the US represents a significant opportunity for players in the Suboxone market. According to the National Institute of Drug Abuse, over 2 million people suffer from opioid use disorder in the US. Suboxone offers an important treatment option for these patients.

Technological advancements are allowing for alternative formulations and delivery methods of Suboxone that could boost patient compliance. New Suboxone films and sublingual tablets offer more accurate dosing and administration compared to traditional strips or tablets.

Market Trends

The shift towards generic versions of Suboxone is a major trend in the market. Loss of exclusivity for branded Suboxone has increased market entry of generic competitors leading to lower prices.

Telehealth and telemedicine are also growing trends, allowing remote monitoring and care for substance abuse patients amid Covid-19. This improves access to addiction treatment including Suboxone therapy.

Market Opportunities

Increasing priority on expanding treatment capacity and availability represents a key opportunity. Greater uptake of medication-assisted treatments, awareness drives, and advocacy efforts can help address the shortfall in treatment availability.
Growth in formulations expanding the options available, including fast-dissolving films and sublingual tablets, opens new markets.

Impact of COVID-19 on United States of America Suboxone Market

The COVID-19 pandemic has adversely impacted the growth of United States of America Suboxone market. During the initial lockdown phases, substance abuse treatment facilities had to temporarily shut down operations due to social distancing norms. Consequently, substance dependent individuals faced difficulties in accessing Suboxone for opioid dependence treatment. This led to a decline in Suboxone demand and sales during 2020-2021. However, with the escalating rate of opioid overdose deaths amid the pandemic, telemedicine emerged as an effective solution to continue providing Suboxone treatment services virtually. Major players also adopted online consultation and home delivery models to ensure undisrupted supply of Suboxone medications. It is expected that greater utilization of telehealth for substance abuse care post-COVID will have a positive influence on the future prospects of the United States of America Suboxone industry. While the immediate term was challenging, the long term outlook remains optimistic driven by rising opioid crisis in the country and expanding acceptance of medication-assisted therapies.

From a geographical perspective, the Midwestern region of the United States accounts for the largest share of value sales of Suboxone in the country. States like Ohio, Michigan, Illinois and Indiana have higher rates of prescription opioid misuse in comparison to other parts of the nation. This is a major factor supporting substantial demand for medication-assisted treatments including Suboxone within this region. Meanwhile, Southern states like Florida, Texas and North Carolina constitute the fastest growing regional market for Suboxone. Heightened availability of illicit fentanyl and increasingly lethal synthetic opioids are fueling opioid addiction epidemics in these southern states, thereby augmenting the patient base seeking Suboxone treatment.

What Are The Key Data Covered In This United States of America Suboxone Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the United States of America Suboxone's growth between 2024 and 2031.

:- Accurate calculation of the size of the United States of America Suboxone and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- United States of America Suboxone Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of United States of America Suboxone vendors

FAQ’s

Q.1 What are the main factors influencing the United States of America Suboxone?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top United States of America Suboxone companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the United States of America Suboxone’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://www.pressreleasebulletin.com/united-states-of-america-suboxone-market-trend-size-and-demand/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)